MannKind (MNKD) has announced promising 30-week results from the Phase 4 INHALE-3 study. The study showed that more patients with type 1 diabetes achieved their target A1c levels during the extension phase. The positive outcomes observed at both the 17-week and 30-week marks reinforce the importance of Afrezza as a viable treatment option for adults managing diabetes.
"The data from this extension phase demonstrates that a greater number of individuals with T1D can achieve their target A1c levels by continuing on Afrezza with basal insulin, or by switching to Afrezza from their usual care methods, whether they use multiple daily injections or pumps," stated Michael Castagna, CEO of MannKind.
